Interpretation of Market Fluctuation: Erasca's Sharp Decline on September 23 — Competitor Comparison, High-Level Pullback, and Small Sample Size

1. On September 22, 2026, Propanc released preclinical data on its pancreatic cancer drug candidate PRP, comparing its efficacy, mechanism of action, and development positioning with Erasca’s phase I data for ERAS-0015, forming key considerations for projects targeting the same indication.
2. As of September 23, 2026, the company’s cumulative increase since the beginning of the year remained at 288.71%, with a cumulative decline of 5.86% over the past five days. Against a backdrop of trading at high levels, there is technical correction pressure and profit-taking in the share price.
3. On July 13, 2026, the company disclosed phase I data for ERAS-0015 in pancreatic cancer. At a dose of 32 mg once daily, the 8-week unconfirmed objective response rate was 57%, but the sample size was only 7 cases, and repeatability of efficacy still requires more clinical data for validation.

(Disclaimer: This content was generated by AI based on publicly available information and is for reference only. It does not constitute investment advice.)